JP2007075540A - Medical material with surface to be displaced with organism tissue - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a medical material having property to be integrated with organism tissue by firmly joining with a living body. <P>SOLUTION: The medical material comprises a surface to be displaced with the organism tissue, which includes at least one active ester radical introduced to a polysaccharide chain and to react with an active hydrogen containing group, is joined with the surface of the tissue by generating chemical adhesion by a covalent generation reaction between the active ester radical and the active hydrogen containing group existing on the surface of the organism tissue when contact is performed with the organism tissue under an alkaline condition, displaces a polysaccharide existing part with the tissue in a process where the polysaccharide joined with the tissue is absorbed into the tissue, and generates firm engagement by allowing the tissue to come into the part on the material surface in place of the polysaccharide. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

The present invention relates to a biological implant material used in a medical field, in particular, an implant material that needs to be kept locally in a body cavity, or a medical device that is placed from outside the body through the skin. .

  As a material to be placed with some necessity in the body cavity of a patient, silicon rubber, polyurethane, etc. that are inert to living tissue are generally used from the viewpoint of safety to the human body.

When these materials are used as implant materials that need to be kept locally in the body cavity, the materials made of such materials are inactive against living tissue, so foreign body reaction is a foreign body. Since encapsulation for isolating the membrane occurs and it is kept away from the main target tissue or organ, it often becomes difficult over time to perform its intended function.

On the other hand, when these materials are used as medical materials that are placed from outside the body through the skin, there is no unity between these materials that are inert to the living tissue and the living tissue. Growth (dissociation from the material due to the extension of the epithelial cells to the material side and the extension of the tissue to the side of the living tissue that comes into contact with the material) occurs, and as a result, a gap is formed. Easy to enter and may cause infection.

It is considered that the above problems can be suppressed by increasing the adhesion between the material and the living tissue by physically increasing the integrity between the material and the living tissue. A method has been proposed in which the surface is made porous, or hydroxyapatite or the like is vapor-deposited on the surface to make it porous (Non-patent Document 1, Patent Document 1).

However, roughening the surface of the material or making it into a complicated shape is not necessarily effective for complicated labor.

On the other hand, since silicon rubber, polyurethane, etc., which are polymer materials, are soft materials, it is difficult to form hydroxyapatite with good adhesion on the surface (Patent Documents 2 and 3).

In addition, when the surface is roughened, the initial cell adhesion rate is increased, but the tissue reaction is strong and tends to be prolonged (Non-patent Document 1), and thus it is difficult to say that its biocompatibility is high.

Junji Imai Effects of macro structure of macromolecules-shape and form-Biomaterial Science, 1st collection (1982)

Japanese Examined Patent Publication No. 6-77602

JP-A-5-57011

Japanese Examined Patent Publication No. 3-27214

The present invention has been made in order to solve the above-mentioned problems in living implantable materials used in the medical field, and the material surface and living tissue are firmly joined and connected while maintaining biocompatibility. This is an issue.

  The problem is that the surface of the material in various forms is coated with an organic solvent containing a polysaccharide derivative that is highly safe in vivo, and the polysaccharide derivative is replaced with the tissue in vivo by contact with the living tissue. This is achieved by providing a medical material having a property of being integrated with a living tissue by being firmly connected to a living body and a method for producing the same, and is achieved by the present invention described in (1) to (16) below.

(1) The surface of the material of various forms is coated and integrated with a composition containing an organic solvent containing a highly safe polysaccharide derivative in vivo, and the polysaccharide derivative and the tissue in vivo are brought into contact with each other by contacting with the living tissue. A medical material having a tissue replacement surface having a property of being integrated with a living tissue by replacing and firmly connecting to the living body, and a method for producing the same.

(2) The polysaccharide derivative has at least one active ester group introduced into a polysaccharide side chain and capable of reacting with an active hydrogen-containing group, and the active ester group is brought into contact with a living tissue under alkaline conditions. In the process where the polysaccharide is bound to the tissue by forming a chemical bond by a covalent bond formation reaction between the active hydrogen-containing group and the active hydrogen-containing group present on the surface of the living tissue, and the polysaccharide bound to the tissue is absorbed into the tissue. The medical material having a biological tissue-replaceable surface according to (1), comprising a reactive polysaccharide derivative having a property of causing firm engagement when the tissue is replaced with a polysaccharide at the site of the material surface by substitution. .

(3) The living body according to (1) or (2), wherein the active hydrogen-containing group is an amino group, a hydroxyl group or a thiol group present on the surface of a living tissue, and the reactive polysaccharide derivative has adhesiveness to the living body surface. A medical material with a tissue-replaceable surface.

(4) The medical material having a biological tissue-replaceable surface according to any one of (1) to (3), wherein the active ester group is an ester group in which an electrophilic group is bonded to the carbonyl carbon.

(5) The medical material having a biological tissue-replaceable surface according to (4), wherein the electrophilic group is a group introduced from an N-hydroxyamine compound.

(6) The medical material having a biological tissue-replaceable surface according to any one of (1) to (5), wherein the active ester group is a succinimide ester group.

(7) The biological tissue-replaceable surface according to any one of (1) to (6), wherein the reactive polysaccharide derivative contains the active ester group in an amount of 0.1 to 2 mmol / g with respect to its dry weight. With medical material.

(8) The medical material having a biological tissue-replaceable surface according to any one of (1) to (7), wherein the reactive polysaccharide derivative further has a carboxy group and / or a carboxyalkyl group.

(9) The medical material having a biological tissue replacement surface according to any one of (1) to (8), wherein the reactive polysaccharide derivative is non-salt type.

(10) The raw polysaccharide into which the active ester group is introduced has a temperature between 60 ° C. and 120 ° C. in its non-salt form in the precursor stage of the crosslinkable polysaccharide derivative having a carboxy group and / or a carboxyalkyl group. The medical material having a biological tissue-replaceable surface according to any one of (1) to (9), which is a polysaccharide that is soluble in an aprotic polar solvent.

(11) The raw tissue-replaceable surface according to any one of (1) to (10), wherein the raw material polysaccharide into which the active ester group is introduced is itself a polysaccharide having no carboxy group and no carboxyalkyl group. Medical materials to have.

(12) The medical material having a biological tissue-replaceable surface according to (11), wherein the raw material polysaccharide is at least one polysaccharide selected from the group consisting of dextran, pullulan, or dextrin.

(13) The biological tissue-replaceable surface according to any one of (1) to (10), wherein the raw material polysaccharide into which the active ester group is introduced is itself a polysaccharide having a carboxy group and / or a carboxyalkyl group. Medical materials to have.

(14) The medical material having a biological tissue-replaceable surface according to (13), wherein the raw material polysaccharide into which the active ester group is introduced is pectin or hyaluronic acid. This raw material polysaccharide is an active esterification precursor (acid group-containing polysaccharide) as it is.

(15) The medical material having a biological tissue-replaceable surface according to any one of (1) to (14), wherein the alkaline condition is in a range of pH 7.5 to 12.

(16) The medical material having a biological tissue-replaceable surface according to any one of (1) to (15), wherein the composition containing the organic solvent contains an arbitrary polymer substance.

According to the present invention, a medical material having a property of being integrated with a living tissue can be provided by being firmly connected to the living body.

The present invention will be specifically described below.

First, the reactive polysaccharide derivative according to the medical material having a tissue replacement surface according to the present invention will be described. The reactive polysaccharide derivative has at least one active ester group introduced into the polysaccharide side chain and capable of reacting with an active hydrogen-containing group. The polysaccharide (raw material) into which the active ester group is introduced will be described later. The polysaccharide derivative in which the active ester group is introduced into the polysaccharide is an amino group that is an active hydrogen-containing group that exists in a living tissue under reaction conditions, Reactive with hydroxyl and thiol groups.

In the present specification, such a reactive polysaccharide derivative may be referred to as an active esterified polysaccharide, and hereinafter, it may be simply referred to as a polysaccharide derivative. The term “single molecular chain” or “intramolecular” means one molecule in a range connected by a continuous bond through a covalent bond.

The polysaccharide derivative according to the present invention is an active esterified polysaccharide and essentially retains the polysaccharide skeleton. Therefore, in the following, the polysaccharide derivative may be described in parallel with the polysaccharide active esterification method (polysaccharide derivative production method).

In the present invention, the active ester group introduced into the polysaccharide may be any group that can react with the active hydrogen-containing group to form a covalent bond in the presence of water under alkaline conditions. Such an active ester group usually has a strong electrophilic group on the carbonyl carbon of a carboxy group or a methylcarboxy group that is self-contained by a polysaccharide molecule or introduced by acidification, as compared with a normal ester. It is a bonded group.

Specifically, when the active ester group is represented by “—COOX”, the electrophilic group forming the alcohol moiety “—OX” is preferably a group introduced from an N-hydroxyamine compound. This is because the N-hydroxyamine compound is a relatively inexpensive raw material, and therefore it is easy to industrially introduce an active ester group.

Specific examples of the N-hydroxyamine compound for forming “-OX” include N-hydroxysuccinimide, N-hydroxynorbornene-2,3-dicarboxylic acid imide, and 2-hydroxyimino-2-cyanoacetic acid. Typical examples include ethyl ester, 2-hydroxyimino-2-cyanoacetamide, N-hydroxypiperidine and the like.

In the present invention, the active ester group of the polysaccharide derivative may be used alone or in combination of two or more. Among such active ester groups, succinimide ester groups are preferred.

The polysaccharide derivative used in the present invention has at least one active ester group in the molecule, but usually has two or more in one molecule in order to form a crosslinked matrix. Although it depends on the purpose of use, it is preferably 0.5 to 2 mmol / g when expressed in terms of the amount of active ester groups per 1 g of the dry weight.

In the present invention, the polysaccharide into which the active ester group is introduced and which constitutes the main skeleton of the polysaccharide derivative is not particularly limited as long as it has two or more monosaccharide structures in the main skeleton. Such polysaccharides are monosaccharides such as arabinose, ribose, xylose, glucose, mannose, galactose, fructose, sorbose, rhamnose, fucose, ribodeose; disaccharides such as trehalose, sucrose, maltose, cellobiose, gentiobiose, lactose, melibiose; Examples include those formed by covalently bonding polysaccharides of three or more sugars such as raffinose, gentianose, meretitol, and stachyose, and those having a functional group introduced thereto.

In the present invention, such polysaccharides may be naturally occurring or artificially synthesized. In addition, the polysaccharide derivative according to the present invention can be a single skeleton or a skeleton of two or more polysaccharides.

There is no restriction | limiting in particular in the weight average molecular weight of the polysaccharide used as the main frame | skeleton of a polysaccharide derivative. Preferably, it is a polysaccharide having a weight average molecular weight of 5,000 to 2,500,000 corresponding to a combination of several tens to several thousands of the above-mentioned monosaccharides, disaccharides, or trisaccharides. More preferably, it is a polysaccharide having a weight average molecular weight of 10,000 to 1,000,000.

The raw material polysaccharide that forms the main skeleton of the polysaccharide derivative has the above-described constituents and has a carboxylic acid group for forming an active ester group “—COOX” in the active esterification precursor stage (hereinafter referred to as an acid group-containing polysaccharide). (Sometimes called polysaccharides). The carboxylic acid group here refers to a carboxy group and / or a carboxyalkyl group (hereinafter sometimes referred to as a carboxylic acid group), and the carboxyalkyl group refers to a carboxymethyl group, a carboxyethyl group, a carboxypropyl group. , A functional group in which a carboxy group is bonded to an alkyl skeleton, as exemplified by carboxyisopropyl group, carboxybutyl group and the like.

The raw material polysaccharide may be an acid group-containing polysaccharide at the precursor stage of the reactive polysaccharide derivative, may be a natural polysaccharide that self-holds a carboxylic acid group, and is itself a polysaccharide that does not have a carboxylic acid group. It may be a polysaccharide introduced with a carboxy group and / or a carboxyalkyl group. Among such carboxylic acid group-containing polysaccharides, natural polysaccharides having a carboxy group, carboxylated polysaccharides introduced with a carboxy group, carboxymethylated polysaccharides introduced with a carboxymethyl group, and carboxyethylated polysaccharides introduced with a carboxyethyl group are preferred. . More preferred are natural polysaccharides having a carboxy group, carboxylated polysaccharides introduced with a carboxy group, and carboxymethylated polysaccharides introduced with a carboxymethyl group.

Although it does not specifically limit as said natural polysaccharide which self-holds the said carboxylic acid group, Pectin, hyaluronic acid, etc. containing galacturonic acid are mentioned. For example, “GENUE pectin” from CP Kelco (Denmark) can be used as the pectin, and “hyaluronic acid FCH” from Kibunsha (Japan) can be used as the hyaluronic acid. Pectin is a polysaccharide mainly composed of galacturonic acid. About 75 to 80% or more of pectin is composed of galacturonic acid, and other components are mainly composed of other sugars. Pectin is a polysaccharide formed by binding galacturonic acid and other sugars at the above ratio. Hyaluronic acid is used as an ophthalmic surgical aid, a knee osteoarthritis therapeutic agent, and the like. Hyaluronic acid does not contain galacturonic acid.

In the present invention, the carboxy group and / or carboxyalkyl group of the polysaccharide derivative is preferably “non-salt type” in which the salt is not coordinated, and the polysaccharide derivative finally obtained is preferably not in the salt form. . Here, the “salt” includes inorganic salts such as alkali metals and alkaline earth metals, quaternary amines such as tetrabutylammonium (TBA), and halogen salts such as chloromethylpyridylium iodide. “Non-salt type” means that these “salts” are not coordinated, and “not in salt form” means that these salts are not included.

The polysaccharide into which the carboxy group and / or carboxyalkyl group is introduced is not particularly limited, and examples thereof include dextran, pullulan, and dextrin.

The above dextran is used as a plasma substitute. Dextran includes "Dextran T fractions" from Amersham Biosciences (Japan), Pullulan from "Pullulan PI-20" from Hayashibara (Japan), and dextrin from "Dextrin Hydrate" from Wako Pure Chemical Industries, Ltd. . Pullulan is used as a pharmaceutical additive including oral drugs, and those with low biological contamination such as endotoxin are suitable. Any polysaccharide that is generally commercially available can be used in the present invention. In the present invention, the polysaccharide having a proven record in the above medical use is a polysaccharide that can be suitably used in terms of safety.

The carboxylation reaction of a polysaccharide can be carried out without particular limitation using a known oxidation reaction. The type of the carboxylation reaction is not particularly limited, and examples thereof include dinitrogen tetroxide oxidation, fuming sulfuric acid oxidation, phosphoric acid oxidation, nitric acid oxidation, and hydrogen peroxide oxidation, each of which is a commonly known reaction using a reagent. Can be selected and oxidized. Each reaction condition can be appropriately set depending on the amount of carboxy group introduced.

For example, by suspending a polysaccharide as a raw material in chloroform or carbon tetrachloride and adding dinitrogen tetroxide, the hydroxyl group of the polysaccharide can be oxidized to prepare a carboxylated polysaccharide (polysaccharide carboxylate). .

In addition, the carboxyalkylation reaction can utilize a known polysaccharide carboxyalkylation reaction, and is not particularly limited. Specifically, in the case of carboxymethylation reaction, monochloroacetic acid is used after alkalizing the polysaccharide. The selected reaction can be selected. The reaction conditions can be appropriately set depending on the amount of carboxymethyl group introduced.

In the present invention, as a method for introducing a carboxylic acid group into a polysaccharide, any of the above-mentioned carboxylation or carboxyalkylation methods can be used, and the method is not particularly limited. Carboxyalkylation, particularly carboxymethylation, is preferred from the viewpoint of relatively easy control of the amount of introduction.

In the present invention, the introduction of a carboxylic acid group is not particularly limited to introduction into a polysaccharide that does not itself have a carboxylic acid group. A carboxy group and / or a carboxymethyl group may be further introduced into a natural polysaccharide having its own carboxylic acid group, for example, the hyaluronic acid.

In the active esterification of the carboxy group and / or carboxymethyl group of the acid group-containing polysaccharide as described above, the acid group-containing polysaccharide may be used alone or in combination of two or more kinds. May be.

The acid group-containing polysaccharide used for the active esterification is usually 0.1 to 5 mmol / g, preferably 0.4, in terms of the amount of carboxylic acid groups per 1 g of dry weight (assuming the group is one molecule). -3 mmol / g, more preferably 0.6-2 mmol / g. When the ratio of the amount of the carboxylic acid group is less than 0.1 mmol / g, the number of active ester groups derived from the group and serving as a crosslinking point is often insufficient. On the other hand, when the ratio of the amount of carboxylic acid groups exceeds 5 mmol / g, the polysaccharide derivative becomes difficult to dissolve in a solvent containing water.

The active esterification method of the acid group-containing polysaccharide (a method for producing a polysaccharide derivative) is not particularly limited. For example, the acid group-containing polysaccharide is combined with an electrophilic group introducing agent in the presence of a dehydration condensing agent. Examples thereof include a method of reaction, a method of using an ester exchange reaction in which an active ester group is introduced into a polysaccharide from a compound having an active ester group. Among these, the former method is suitable for the present invention, and this method (also referred to as the method of the present invention) will be mainly described below.

In carrying out the preferred method of the present invention, the acid group-containing polysaccharide is usually prepared in a solution of an aprotic polar solvent and subjected to the reaction. More specifically, the method includes a solution preparation step in which a polysaccharide having a carboxy group or a carboxyalkyl group is dissolved in an aprotic polar solvent, and an electrophilic group introducing agent and a dehydrating condensing agent are added to the solution. Examples include a method of performing a reaction step of esterifying a carboxy group or a carboxyalkyl group of a polysaccharide, and a method of performing a purification step and a drying step of the reaction product.

In the solution preparation step, the polysaccharide is added to the solvent and heated to 60 ° C. to 120 ° C., whereby the polysaccharide is dissolved in the aprotic polar solvent. Therefore, as the acid group-containing polysaccharide to be active esterified by this method, among the polysaccharides exemplified above, those that dissolve in an aprotic polar solvent at a temperature between 60 ° C. and 120 ° C. are preferably used.

Specifically, the polysaccharide used in the reaction for introducing the electrophilic group preferably has a carboxy group or a carboxymethyl group in an acid form from the viewpoint of solubility in an aprotic polar solvent. “Acid type” means that the cation group of the carboxy group or carboxymethyl group is a proton. A polysaccharide having an acid-type carboxy group is called an acid-type (raw material) polysaccharide.

For example, pectin, which is a polysaccharide having a carboxy group, is called acid-type pectin. Carboxymethyldextran having an acid-type carboxymethyl group is referred to as acid-type carboxymethyl (CM) dextran (acid-type CM dextran). The “acid type” is synonymous with the “non-salt type” in that the counter cation species is a proton and is not in a salt form.

An “aprotic polar solvent” is a polar solvent that does not have a proton capable of forming a hydrogen bond with a nucleophile having an electrically positive functional group. The aprotic polar solvent that can be used in the production method according to the present invention is not particularly limited, but dimethyl sulfoxide (DMSO), N, N-dimethylformamide, N-methyl-2-pyrrolidone, N, N-dimethylacetamide, 1 , 3-dimethyl-2-imidazolidinone. Dimethyl sulfoxide can be suitably used because the solubility of the polysaccharide in the solvent is good.

In the reaction step, an electrophilic group-introducing agent and a dehydrating condensing agent are added to the acid-type polysaccharide solution to cause the carboxy group and / or carboxymethyl group of the polysaccharide to be active esterified. Although the reaction temperature at the time of carrying out active esterification is not specifically limited, Preferably it is 0 to 70 degreeC, More preferably, it is 20 to 40 degreeC. While the reaction time varies depending on the reaction temperature, it is generally 1 to 48 hours, preferably 12 to 24 hours.

The “electrophilic group introduction agent” refers to a reagent that introduces an electrophilic group into a carboxy group or a carboxyalkyl group and converts them into an active ester group. Although it does not specifically limit as an electrophilic group introduction | transduction agent, The active ester derivative compound widely used for peptide synthesis can be utilized, N-hydroxyamine type | system | group active ester derivative compound is mentioned as an example. The N-hydroxyamine-based active ester-derived compound is not particularly limited. For example, N-hydroxysuccinimide, N-hydroxynorbornene-2,3-dicarboxylic imide, 2-hydroxyimino-2-cyanoacetic acid ethyl ester, Examples include 2-hydroxyimino-2-cyanoacetamide, N-hydroxypiperidine and the like. Among these, N-hydroxysuccinimide is more preferable because it has a track record in the field of peptide synthesis and is easily available commercially.

The “dehydration condensing agent” is a condensation of a carboxy group or a carboxyalkyl group with an electrophilic group introducing agent when an electrophilic group introducing agent is used for the carboxy group or carboxyalkyl group to form an active ester group. One water molecule to be generated is extracted, that is, dehydrated, and both are ester-bonded. The dehydrating condensing agent is not particularly limited. For example, 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (EDC / HCl), 1-cyclohexyl- (2-morpholin-4-ethyl) -carbodiimide / meso p- And toluene sulfonate. Among these, 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (EDC · HCl) is more preferable because it has a track record in the peptide synthesis field and is easily available commercially.

In the purification process, after the completion of the reaction process, the unreacted electrophilic group introducing agent, dehydrating condensing agent, and reaction by-products are removed from the reaction solution by means such as ordinary reprecipitation, filtration and / or washing. Thus, the polysaccharide derivative according to the present invention can be obtained.

In the drying step, in order to remove the washing solvent from the polysaccharide derivative obtained in the purification step, it may be dried by a commonly used method.

In the present invention, as described above, the amount of the active ester group of the polysaccharide derivative is preferably 0.1 to 2 mmol / g in the end, and in the above, the activity is performed so that such a polysaccharide derivative is obtained. The amount of the active ester group introduced into the carboxy group of the esterified raw material polysaccharide can be controlled.

In order to control the introduction amount of the active ester group, the mixing amount of the electrophilic group introduction agent and the dehydration condensing agent can be adjusted in the reaction step. Specifically, the ratio (Z / X) of the number of moles (Zmmol) of the dehydration condensing agent to the number of moles (Xmmol) of all carboxy groups of the polysaccharide is 0.1 <Z / X <50 at the reaction temperature described above. It is preferable that the addition conditions satisfy the conditions. When Z / X is less than 0.1, the reaction efficiency is low because the addition amount of the dehydrating condensing agent is small, making it difficult to achieve the desired active ester group introduction rate. When Z / X is greater than 50, the dehydrating condensing agent This is because, although the amount of the active ester group introduced is high, the resulting polysaccharide derivative becomes hydrophobic and its adhesion to living tissue is reduced.

The number of moles (Ymmol) of the electrophilic group-introducing agent relative to the number of moles (Xmmol) of all carboxy groups of the polysaccharide is not particularly limited as long as the reaction amount or more according to the introduction rate of the active ester group is added. It is preferable that the addition conditions satisfy 1 <Y / X <100.

The introduction rate (%) of the active ester group is obtained with respect to the carboxy group-containing molar amount and the carboxymethyl group-containing molar amount (hereinafter referred to as total carboxy group (TC)) of the polysaccharide of the active esterification raw material. The ratio (AE / TC) of the molar amount (AE) of active ester groups in the polysaccharide derivative can be expressed by multiplying by 100. The active ester group introduction rate can be determined, for example, by the method described in Biochemistry Vol. 14, No. 7 (1975), p1535-1541.

In particular, it may have a carboxy group and / or a carboxymethyl group of the remaining raw material polysaccharide when the active ester group is introduced at an introduction rate of the active ester group of less than 100%.

In the present invention, the active hydrogen-containing group involved in the reaction with the active ester group is not particularly limited as long as it is a group capable of reacting with the active ester group to form a covalent bond under the reaction conditions specific to the present invention.

In the present invention, the adhesion between the polysaccharide derivative and the biological tissue is based on the formation of a covalent bond by the reaction between the active ester group and the active hydrogen group. Specifically, a method of forming a covalent bond by bringing a polysaccharide derivative into contact with the surface of a biological tissue containing water, water vapor, and water under alkaline conditions can be mentioned.

More specifically, when the surface of a transdermal device coated with a polysaccharide derivative is in contact with a biological tissue, the polysaccharide derivative is used in the presence of water at pH 7.5 to 12, preferably pH 9.0 to 10.5. A covalent bond can be formed between active hydrogen groups on the surface of a living tissue. At this time, if the pH of water is lower than 7.5, the covalent bond forming property is low and sufficient adhesion cannot be obtained. On the other hand, application of a material having a pH higher than 12 is not preferable in terms of physiological conditions although the covalent bond forming reaction proceeds.

In the present invention, “alkaline conditions” refer to conditions in which water having a pH of at least 7.5 or more is present. In the reactive polysaccharide derivative according to the present invention, since the contribution of heat to the covalent bond forming reaction is not substantially large, the temperature of “alkaline conditions” is not particularly limited, but is, for example, in the range of 10 ° C. to 40 ° C. be able to. “Contacting water under alkaline conditions” means contacting the polysaccharide derivative with any form of water under alkaline conditions to place the polysaccharide derivative under alkaline conditions.

The alkalizing agent is not particularly limited, and specific examples thereof include an aqueous sodium hydrogen carbonate solution, a phosphate buffer solution (disodium hydrogen phosphate-potassium dihydrogen phosphate), and an acetic acid-ammonia buffer solution. Among these, sodium bicarbonate can be suitably used from the viewpoint of safety because a 7% aqueous solution (pH 8.3) thereof is used as an intravenous injection solution as a medical pH adjuster.

The medical material having a biological tissue-replaceable surface according to the present invention is provided by allowing a polysaccharide derivative that forms a covalent bond with the biological tissue as described above to exist on the biological tissue contact surface of various types of medical materials. be able to.

The medical material having a biological tissue-replaceable surface according to the present invention includes various compositions containing a solvent (B) that can dissolve or disperse the reactive polysaccharide derivative (the composition contains a polymer substance). A polymeric substance containing a reactive polysaccharide derivative or a reactive polysaccharide derivative that is applied to a medical material in a form, applied to a portion where the living tissue of the material comes into contact, and volatilizes the solvent (B) It can manufacture by coating with. The solvent (B) capable of dissolving or dispersing the reactive polysaccharide derivative is not particularly limited as long as it dissolves or disperses the reactive polysaccharide derivative (A).

For example, water, dimethyl sulfoxide, dimethylformamide, dimethylacetamide and the like can be mentioned. The solvent (B) is preferably 100 to 4000 parts by mass with respect to 100 parts by mass of the reactive polysaccharide derivative. The amount of the solvent (B) is more preferably 100 to 2000 parts by mass with respect to 100 parts by mass of the reactive polysaccharide derivative. As the coating method, various known coating methods such as spin coating, flow coating, and roll coating can be employed. The polymer substance to be included in the composition can be any polymer substance that can be dissolved in the solvent (B), but preferably a high molecular weight material known to form a biocompatible surface after curing. Molecules such as poly (tetrahydrofurfuryl acrylate) (PTHFA), poly (2-methoxyethylacrylate) (PMEA) and the like are preferred. Arbitrary polymeric materials are preferable as the material of various forms which should become the base material of this material. Ceramic materials or metal materials are acceptable, but in that case, the coating may fall off due to poor bonding with the composition containing the solvent (B) that can dissolve or disperse the coated reactive polysaccharide derivative. Further steps are required such as making the coating material easier to anchor to the substrate side by processing such as roughening the surface of the material to be coated.

Next, the principle that the surface of the medical material of the present invention has replaceability with living tissue will be described.

The polysaccharide derivatives placed on the surface of this material by the method described above are present on the surface of this material in a uniformly dispersed state, and these polysaccharides are active ester groups and the activity present on the surface of biological tissue. It binds to a living tissue by a covalent bond forming reaction with a hydrogen-containing group, and attracts the living tissue to the material surface. The attracted biological tissue is in close contact with the surface of the material, and at the site where the polysaccharide is present, the bonded polysaccharide portion is in the form of biting into the surface of the material. This polysaccharide eventually replaces self-organized tissue mainly consisting of collagen fibers (collagen), and as a result, the bite-in part is self-organized, as if the biological tissue meshes with the material surface. A simple porous material does not have the above-mentioned attracting factors, so unless the tissue is actively attracted by factors that proliferate cells and tissues, the tissue will bite into the pores so as to form a strong mesh like this material. Absent.

EXAMPLES The present invention will be described more specifically with reference to the following examples. However, these are shown as examples, and the present invention is not limited to these examples.

(Synthesis Example 1)
Preparation of raw material polysaccharide (acid type polysaccharide) Carboxymethyl dextrin (acid type CM dextrin) was prepared as a raw material polysaccharide used as a raw material of the active esterified polysaccharide derivative. After adding 62.5 g of pure water to 10 g of dextrin (Wako Pure Chemical Industries, Ltd., weight average molecular weight 25000) and dissolving, add 62.5 g of 36% sodium hydroxide aqueous solution (sodium hydroxide, Wako Pure Chemical Industries, Ltd.) After stirring for 90 minutes at 25 ° C. and dissolution, 75 g of 15% monochloroacetic acid (W / V) (monochloroacetic acid, Wako Pure Chemical Industries, Ltd.) was added and stirred at 60 ° C. for 6 hours. Thereafter, the reaction solution was adjusted to pH 1.0 using 20% hydrochloric acid and stirred at 25 ° C. for 2 hours. The reaction solution was dropped into 5 L of 90 vol% ethanol aqueous solution (100% ethanol, manufactured by Wako Pure Chemical Industries, Ltd.), and the precipitate was collected using a suction funnel. The precipitate obtained by using 3 L of 90 vol% ethanol aqueous solution was washed, finally replaced with ethanol, and then dried under reduced pressure. In this way, acid type CM dextrin was prepared.

(2) Quantification of carboxy group or carboxymethyl group The acid type CM dextrin (raw material polysaccharide) obtained in (1) above was quantified. 0.2 g (A (g)) of raw material polysaccharide was weighed and added to a mixed solution of 20 ml of 0.1 mol / L sodium hydroxide aqueous solution and 10 ml of 80 vol% methanol aqueous solution, and stirred at 25 ° C. for 3 hours. To the resulting solution, add 3 drops of 1.0% phenolphthalein (W / V) 90vol% aqueous ethanol solution as an indicator, and perform acid-base back titration with 0.05mol / l sulfuric acid. The amount used (V1 ml) was measured (phenolphthalein, manufactured by Wako Pure Chemical Industries, Ltd.). Moreover, the usage-amount (V0 ml) of 0.05 mol / l sulfuric acid in the blank performed similarly except not adding raw material polysaccharide was measured. According to the following formula (1), the amount (Bmmol / g) of the carboxy group and carboxymethyl group of the raw material polysaccharide was calculated to be 1.26 mmol / g. The titers of the 0.1 mol / l sodium hydroxide aqueous solution and 0.05 mol / l sulfuric acid used were both 1.00.
B = (V0-V1) × 0.1 ÷ A ……… (1)
A: Mass of raw polysaccharide (g)
B: Group amount of carboxy group and carboxymethyl group (mmol / g)

(3) Preparation of active esterified CM dextrin For the active esterification reaction of acid-type CM dextrin, the reaction solvent is DMSO, the electrophilic group introducing agent is N-hydroxysuccinimide (NHS) (manufactured by Wako Pure Chemical Industries, Ltd.), The dehydrating condensing agent is 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (EDC) (manufactured by Wako Pure Chemical Industries, Ltd.)
Was used to prepare an active esterified polysaccharide. 3.0 g of CM dextrin (carboxymethyl group amount 1.26 mmol / g) obtained in the above (1) was added to 90 g of DMSO, and dissolved by stirring at 70 ° C. for 3 hours. Then, NHS 4.35g (37.8mmol) and EDC7.22g (37.8mmol) were added, and it stirred at 25 degreeC for 24 hours. The reaction solution was added dropwise to 2 L of anhydrous acetone, and the precipitate was collected using a suction funnel. The precipitate obtained using 1 L of anhydrous acetone was washed and dried under reduced pressure. Thereby, an active esterified CM dextrin was prepared. The ratio of Z / X and Y / X is as follows.
Z / X = 10, Y / X = 10

(4) Calculation of NHS introduction amount of active esterified polysaccharide (polysaccharide derivative) With respect to the active esterification CM dextrin obtained in (3), the NHS introduction amount obtained as follows was 0.8 mmol / g. .
The NHS introduction amount is the NHS content present per unit weight of the polysaccharide derivative.
In order to prepare a calibration curve for N-hydroxysuccinimide (NHS), 0.1, 0.2, 0.5, 1.0, and 2.5 mM NHS standard aqueous solutions were prepared. 0.2 ml of 2N sodium hydroxide aqueous solution was added to 1 ml of each NHS standard aqueous solution, heated at 60 ° C. and stirred for 10 minutes. After allowing to cool, 1.5 ml of 0.85N hydrochloric acid and 0.5 ml of 0.5% FeCl3 / 1N hydrochloric acid solution were added, and the absorbance at an absorption wavelength of 500 nm was measured using a spectrophotometer (FeCl3 Wako Pure Chemical Industries, Ltd.). The concentration of each NHS aqueous solution was plotted with the X axis and the absorbance as the Y axis, and linear approximation was performed to obtain the following formula (2) for calculating the NHS concentration.
Y = αX + β ......... (2)
X: NHS concentration (mM)
Y: Absorbance α = 0.178 at a wavelength of 500 nm (slope)
β = 0.021 (intercept)
γ = 0.995 (correlation coefficient)
Based on the absorbance, NHS concentration, X (mM) is calculated.

Next, 0.01 g (C (g)) of the active esterified polysaccharide (3) was weighed and added to 1 ml of pure water, stirred at 25 ° C. for 3 hours, and then 0.2 ml of 2N aqueous sodium hydroxide solution was added. The mixture was heated at 60 ° C. and stirred for 10 minutes. After cooling to room temperature, 1.5 ml of 0.85N hydrochloric acid was added. After removing the insoluble matter from the obtained solution containing insoluble matter using filter cotton, 0.5 ml of 0.5% FeCl3 / 1N hydrochloric acid solution was added, and the absorbance at an absorption wavelength of 500 nm was measured using a spectrophotometer. (FeCl3 Wako Pure Chemical Industries, Ltd.) When the absorbance measurement value exceeded the absorbance when the NHS standard solution concentration was 5 mM, it was diluted with pure water (dilution ratio H). The NHS concentration (D mmol) of the active esterified polysaccharide was calculated from the absorbance measurement using the formula (2) for calculating the NHS concentration. Subsequently, the NHS group introduction amount of the active esterified polysaccharide was determined from the following mathematical formula (3).
NHS group introduction amount (mmol / g) = (D x H) x 0.001 ÷ C (3)

(Synthesis example 2)
Preparation of Raw Material Polysaccharide (Acid Type Polysaccharide) Carboxymethyl dextran (acid type CM dextran) was prepared as a raw material polysaccharide used as a raw material for the active esterified polysaccharide derivative.
After adding 125 g of 18% sodium hydroxide aqueous solution (sodium hydroxide, manufactured by Wako Pure Chemical Industries, Ltd.) to 10 g of dextran (Dextran T-40, Amersham Biosciences, weight average molecular weight 40000), and stirring and dissolving at 25 ° C. for 90 minutes. 75% of 20% monochloroacetic acid (W / V) (monochloroacetic acid, Wako Pure Chemical Industries, Ltd.) was added and stirred at 60 ° C. for 6 hours. Thereafter, the reaction solution was adjusted to pH 1.0 using 20% hydrochloric acid and stirred at 25 ° C. for 2 hours. The reaction solution was dropped into 5 L of 90 vol% ethanol aqueous solution (100% ethanol, manufactured by Wako Pure Chemical Industries, Ltd.), and the precipitate was collected using a suction funnel. The precipitate obtained by using 3 L of 90 vol% ethanol aqueous solution was washed, finally replaced with ethanol, and then dried under reduced pressure. In this way, acid-type CM dextran was prepared.

(2) Quantification of carboxy group or carboxymethyl group The determination was performed in the same manner as in the case of acid-type CM dextrin described in Synthesis Example 1 (2).
The amount of carboxymethyl group of CM dextran obtained in (1) above was 1.01 mmol / g.

(3) Preparation of active esterified CM dextran For the active esterification reaction of acid-type CM dextran, the reaction solvent is DMSO, the electrophilic group introducing agent is N-hydroxysuccinimide (NHS) (manufactured by Wako Pure Chemical Industries, Ltd.), As the dehydrating condensing agent, 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (EDC) (manufactured by Wako Pure Chemical Industries, Ltd.) was used to prepare an active esterified polysaccharide.
2.0 g of acid-type CM dextran (carboxymethyl group content 1.01 mmol / g) obtained in (1) above was added to 200 g of DMSO, and dissolved by stirring at 70 ° C. for 3 hours. Thereafter, 2.32 g (20.2 mmol) of NHS and 3.86 g (20.2 mmol) of EDCl were added and stirred at 25 ° C. for 24 hours. The reaction solution was added dropwise to 2 L of anhydrous acetone, and the precipitate was collected using a suction funnel. The precipitate obtained using 1 L of anhydrous acetone was washed and dried under reduced pressure. Thereby, active esterified CM dextran was prepared. The ratio of Z / X and Y / X is as follows.
Z / X = 10, Y / X = 10

(4) Calculation of NHS introduction amount of active esterified polysaccharide (polysaccharide derivative) The same method as in the case of active esterified CM dextrin described in Synthesis Example 1 (4) was performed. The NHS introduction amount of the active esterified CM dextran obtained in (3) was 0.4 mmol / g.

(Synthesis Example 3)
Preparation of raw material polysaccharide (acid type polysaccharide) Carboxymethyl hydroxyethyl starch (acid type CM hydroxyethyl starch) was prepared as a raw material polysaccharide used as a raw material of the active esterified polysaccharide derivative.
After adding 125 g of 18% sodium hydroxide aqueous solution (sodium hydroxide, manufactured by Wako Pure Chemical Industries, Ltd.) to 10 g of hydroxyethyl starch (Coatmaster Sanki Co., Ltd., weight average molecular weight 200,000) and dissolving by stirring for 90 minutes at 25 ° C, 75 g of 20% monochloroacetic acid (W / V) (monochloroacetic acid, Wako Pure Chemical Industries, Ltd.) was added and stirred at 60 ° C. for 6 hours. Thereafter, the reaction solution was adjusted to pH 1.0 using 20% hydrochloric acid and stirred at 25 ° C. for 2 hours. The reaction solution was dropped into 5 L of 90 vol% ethanol aqueous solution (100% ethanol, manufactured by Wako Pure Chemical Industries, Ltd.), and the precipitate was collected using a suction funnel. The precipitate obtained by using 3 L of 90 vol% ethanol aqueous solution was washed, finally replaced with ethanol, and then dried under reduced pressure. In this way, acid type CM hydroxyethyl starch was prepared.

(2) Quantification of carboxy group or carboxymethyl group The determination was performed in the same manner as in the case of acid-type CM dextrin described in Synthesis Example 1 (2).
The amount of carboxymethyl group in the CM hydroxyethyl starch obtained in the above (1) was 0.72 mmol / g.

(3) Preparation of active esterified CM hydroxyethyl starch For the active esterification reaction of acid type CM hydroxyethyl starch, DMSO was used as the reaction solvent, and N-hydroxysuccinimide (NHS) was used as the electrophilic group introducing agent (Wako Pure Chemical Industries, Ltd.) 1) -ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (EDC) (manufactured by Wako Pure Chemical Industries, Ltd.)
Was used to prepare an active esterified polysaccharide.
2.0 g of CM hydroxyethyl starch (carboxymethyl group amount 0.72 mmol / g) obtained in (1) above was added to 200 g of DMSO and dissolved by stirring at 70 ° C. for 3 hours. Thereafter, 1.66 g (14.4 mmol) of NHS and 1.38 g (7.2 mmol) of EDC were added, and the mixture was stirred at 25 ° C. for 24 hours. The reaction solution was added dropwise to 2 L of anhydrous acetone, and the precipitate was collected using a suction funnel. The precipitate obtained using 1 L of anhydrous acetone was washed and dried under reduced pressure. This prepared active esterified CM hydroxyethyl starch. The ratio of Z / X and Y / X is as follows. Z / X = 5, Y / X = 10

(4) Calculation of NHS introduction amount of active esterified polysaccharide (polysaccharide derivative) The same method as in the case of active esterified CM dextrin described in Synthesis Example 1 (4) was performed. The NHS introduction amount of the active esterified CM hydroxyethyl starch obtained in (3) was 0.19 mmol / g.

(Synthesis Example 4)
Preparation of Raw Material Polysaccharide (Acid Type Polysaccharide) Carboxymethyl pullulan (acid type CM pullulan) was prepared as a raw material polysaccharide used as a raw material for the active esterified polysaccharide derivative. After adding 125 g of 18% sodium hydroxide aqueous solution (sodium hydroxide, manufactured by Wako Pure Chemical Industries, Ltd.) to 10 g of pullulan (PU101 Hayashibara Institute of Biological Sciences, weight average molecular weight 100000) and dissolving it by stirring at 25 ° C. for 90 minutes, 75 g of 20% monochloroacetic acid (W / V) (monochloroacetic acid, Wako Pure Chemical Industries, Ltd.) was added and stirred at 60 ° C. for 6 hours. Thereafter, the reaction solution was adjusted to pH 1.0 using 20% hydrochloric acid and stirred at 25 ° C. for 2 hours. The reaction solution was dropped into 5 L of 90 vol% ethanol aqueous solution (100% ethanol, manufactured by Wako Pure Chemical Industries, Ltd.), and the precipitate was collected using a suction funnel. The precipitate obtained by using 3 L of 90 vol% ethanol aqueous solution was washed, finally replaced with ethanol, and then dried under reduced pressure. In this way, acid-type CM pullulan was prepared.

(2) Quantification of carboxy group or carboxymethyl group The determination was performed in the same manner as in the case of acid-type CM dextrin described in Synthesis Example 1 (2). The amount of carboxymethyl group of CM pullulan obtained in the above (1) was 0.79 mmol / g.

(3) Preparation of active esterified CM pullulan For the active esterification reaction of acid-type CM pullulan, the reaction solvent is DMSO, the electrophilic group introducing agent is N-hydroxysuccinimide (NHS) (manufactured by Wako Pure Chemical Industries, Ltd.), As the dehydrating condensing agent, 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (EDC) (manufactured by Wako Pure Chemical Industries, Ltd.) was used to prepare an active esterified polysaccharide.
2.0 g of CM pullulan (carboxymethyl group content 0.79 mmol / g) obtained in (1) above was added to 200 g of DMSO, and dissolved by stirring at 70 ° C. for 3 hours. Thereafter, 1.82 g (15.8 mmol) of NHS and 1.51 g (7.9 mmol) of EDC were added, and the mixture was stirred at 25 ° C. for 24 hours. The reaction solution was added dropwise to 2 L of anhydrous acetone, and the precipitate was collected using a suction funnel. The precipitate obtained using 1 L of anhydrous acetone was washed and dried under reduced pressure. Thereby, active esterified CM pullulan was prepared. The ratio of Z / X and Y / X is as follows. Z / X = 5, Y / X = 10

(4) Calculation of NHS introduction amount of active esterified polysaccharide (polysaccharide derivative) The same method as in the case of active esterified CM dextrin described in Synthesis Example 1 (4) was performed. The NHS introduction amount of the active esterified CM pullulan obtained in (3) was 0.20 mmol / g.

(Synthesis Example 5)
(1) Preparation of raw material polysaccharide (acid type polysaccharide) A carboxymethyl highly branched cyclic dextrin (acid type CM highly branched cyclic dextrin) was prepared as a raw material polysaccharide used as a raw material of the active esterified polysaccharide derivative.
After adding 62.5 g of pure water to 10 g of highly branched cyclic dextrin (trade name cluster dextrin, manufactured by Ezaki Glico Co., Ltd., weight average molecular weight 163000) and dissolving, 36% sodium hydroxide aqueous solution (sodium hydroxide, Wako Pure Chemical Industries, Ltd.) After adding 62.5 g and stirring at 25 ° C for 90 minutes, 75 g of 15% monochloroacetic acid (W / V) (monochloroacetic acid, Wako Pure Chemical Industries) was added and stirred at 60 ° C for 6 hours. did. Thereafter, the reaction solution was adjusted to pH 1.0 using 20% hydrochloric acid and stirred at 25 ° C. for 2 hours. The reaction solution was dropped into 5 L of 90 vol% ethanol aqueous solution (100% ethanol, manufactured by Wako Pure Chemical Industries, Ltd.), and the precipitate was collected using a suction funnel. The precipitate obtained by using 3 L of 90 vol% ethanol aqueous solution was washed, finally replaced with ethanol, and then dried under reduced pressure. Thereby, acid-type CM highly branched cyclic dextrin was prepared.

(2) Quantification of carboxy group or carboxymethyl group The determination was performed in the same manner as in the case of acid-type CM dextrin described in Synthesis Example 1 (2). The amount of carboxymethyl group in the CM highly branched cyclic dextrin obtained in (1) above was 1.27 mmol / g.

(3) Preparation of active esterified CM highly branched cyclic dextrin For the active esterification of acid CM highly branched cyclic dextrin, the reaction solvent is DMSO, and the electrophilic group introducing agent is N-hydroxysuccinimide (NHS) (Wako Pure) 1) -Ethyl-3-dimethylaminopropylcarbodiimide hydrochloride (EDC) (manufactured by Wako Pure Chemical Industries, Ltd.) was used as the dehydrating condensing agent, and an active esterified polysaccharide was prepared.
3.0 g of CM highly branched cyclic dextrin (carboxymethyl group amount 1.27 mmol / g) obtained in (1) above was added to 90 g of DMSO and dissolved by stirring at 70 ° C. for 3 hours. Then, NHS 4.38g (38.1mmol) and EDC3.64g (19.05mmol) were added, and it stirred at 25 degreeC for 24 hours. The reaction solution was added dropwise to 2 L of anhydrous acetone, and the precipitate was collected using a suction funnel. The precipitate obtained using 1 L of anhydrous acetone was washed and dried under reduced pressure. Thereby, active esterified CM highly branched cyclic dextrin was prepared. The ratio of Z / X and Y / X is as follows. Z / X = 5, Y / X = 10

(4) Calculation of NHS introduction amount of active esterified polysaccharide (polysaccharide derivative) The same method as in the case of active esterified CM dextrin described in Synthesis Example 1 (4) was performed. The NHS introduction amount of the active esterified CM highly branched cyclic dextrin obtained in (3) was 0.53 mmol / g.

Example 1
An untreated urethane film (1) and a 10% solution of poly (tetrahydrofurfuryl acrylate) (PTHFA) coated on the urethane film (2), and a 5% solution of poly (tetrahydrofurfuryl acrylate) (PTHFA) on the urethane film (3) coated with a mixture of 5% solution of active esterified CM highly branched cyclic dextrin (CMDRI), which is the product of the present invention (3), and formed into a 1cm square film, The change over time was examined by implanting in a subcutaneous pocket prepared on the shaved back.

Two weeks after implantation, (1) and (2) were present free from tissues in the capsule under the naked eye, and could be easily removed with tweezers when the capsule was incised. (3) could not be easily separated from the organization in the encapsulation. When the tissue specimen was prepared, in (1) and (2), a free tissue image was observed in the capsule without being engaged with the tissue (Fig. 1-Photo 1, Fig. 2-Photo 2), ( In 3), an image meshing with the tissue was observed (Fig. 3-Photo 3). Engagement with the tissue is observed at the arrow (→) in the photograph.
It was confirmed that the engagement with the organization made it difficult to diverge and improved the adhesion with the organization.

The drawing substitute photograph which shows a mode that the un-processed polyurethane film is releasing from the structure | tissue. A drawing-substituting photo showing the PTHFA 10% -treated film released from the tissue. The drawing substitute photograph which shows a mode that the film which concerns on this invention has meshed | engaged with the structure | tissue.

Claims (16)

  The surface of various forms of materials is coated and integrated with a composition containing an organic solvent containing a polysaccharide derivative that is highly safe in vivo, and the polysaccharide derivative and the tissue in vivo are replaced by contact with the living tissue. A medical material having a tissue replacement surface having a property of being integrated with a living tissue by being firmly connected to the living body, and a method for producing the same.   The polysaccharide derivative has at least one active ester group introduced into a polysaccharide side chain and capable of reacting with an active hydrogen-containing group, and the active ester group and the biological tissue are brought into contact with the biological tissue under alkaline conditions. The site where the polysaccharide is replaced by the tissue in the process of binding to the tissue surface by forming a chemical bond by a covalent bond formation reaction with the active hydrogen-containing group present on the surface, and the polysaccharide bound to the tissue is absorbed into the tissue The medical material having a biological tissue-replaceable surface according to (1), which comprises a reactive polysaccharide derivative having a property of causing firm engagement when the tissue is replaced with a polysaccharide at the site on the material surface.   The tissue replacement property according to (1) or (2), wherein the active hydrogen-containing group is an amino group, a hydroxyl group or a thiol group present on the surface of a living tissue, and the reactive polysaccharide derivative has adhesiveness to the surface of the living body. Medical material with a surface.   The medical material having a biological tissue-replaceable surface according to any one of (1) to (3), wherein the active ester group is an ester group in which an electrophilic group is bonded to the carbonyl carbon.   The medical material having a biological tissue-replaceable surface according to (4), wherein the electrophilic group is a group introduced from an N-hydroxyamine compound.   The medical material having a biological tissue-replaceable surface according to any one of (1) to (5), wherein the active ester group is a succinimide ester group.   The medical having the biological tissue-replaceable surface according to any one of (1) to (6), wherein the reactive polysaccharide derivative contains the active ester group in an amount of 0.1 to 2 mmol / g with respect to its dry weight. Materials.   The medical material having a biological tissue-replaceable surface according to any one of (1) to (7), wherein the reactive polysaccharide derivative further has a carboxy group and / or a carboxyalkyl group.   The medical material having a biological tissue replacement surface according to any one of (1) to (8), wherein the reactive polysaccharide derivative is non-salt type.   In the precursor stage of the crosslinkable polysaccharide derivative having a carboxy group and / or a carboxyalkyl group, the raw polysaccharide into which the active ester group is introduced is in its non-salt form at a temperature between 60 ° C. and 120 ° C. The medical material having a biological tissue-replaceable surface according to any one of (1) to (9), which is a polysaccharide that is soluble in a protic polar solvent.   The raw material polysaccharide into which the active ester group is introduced is a polysaccharide which itself does not have a carboxy group and a carboxyalkyl group, and has a biological tissue-replaceable surface according to any one of (1) to (10) material.   The medical material having a biological tissue replacement surface according to (11), wherein the raw material polysaccharide is at least one polysaccharide selected from the group consisting of dextran, pullulan, or dextrin.   The raw material polysaccharide into which the active ester group is introduced is a polysaccharide having a carboxy group and / or a carboxyalkyl group, and has a biological tissue-replaceable surface according to any one of (1) to (10) material.   The medical material having a biological tissue-replaceable surface according to (13), wherein the raw material polysaccharide into which the active ester group is introduced is pectin or hyaluronic acid.   The medical material having a biological tissue-replaceable surface according to any one of (1) to (14), wherein the alkaline condition is in a range of pH 7.5 to 12. The medical material having a biological tissue-replaceable surface according to any one of (1) to (15), wherein the composition containing the organic solvent contains an arbitrary polymer substance.

Images